Attovia Therapeutics Inc.

ATTO | NASDAQ

Price Alert Chart Builder DCF Calculator

$21.30

-$0.84 (-3.79%)

At close: Sep 21, 2026, 4:00 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Overview Market Cap Employees

Company Profile

A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis. Its pipeline also includes multi-specific candidates for other inflammatory diseases.

Key Executives

Name	Position
Tao Fu	CEO, President & Director
Hangjun Zhan	Chief Technology Officer
Steven Chan	Chief Financial Officer
Bora Han	VP & Head of Preclinical Development
Hubert C. Chen	Chief Medical Officer
Petter Veiby	Chief Scientific Officer
Zaneta Odrowaz	Chief Business Officer, Treasurer & Secretary

Latest SEC Filings

Date	Type	Title
Sep 02, 2026	10-Q	Quarterly Report
Sep 02, 2026	8-K	Current Report
Aug 28, 2026	4/A	[Amend] Filing
Aug 28, 2026	4/A	[Amend] Filing
Aug 13, 2026	4	Filing
Aug 13, 2026	4	Filing
Aug 12, 2026	SC 13G	Statement of acquisition of beneficial ownership b...
Aug 11, 2026	SC 13D	Filing
Aug 10, 2026	4	Filing
Aug 10, 2026	4	Filing

View All SEC Filings ➞

Attovia Therapeutics Inc.

Country	United States
IPO Date	Aug 4, 2026
Industry	Biotechnology
Sector	Healthcare
Employees	44
CEO	Tao Fu

Contact Details

1091 Industrial Rd, Ste 310 San Carlos, California 94070 United States

https://www.attovia.com

Stock Details

Ticker Symbol	ATTO
Exchange	NASDAQ
Fiscal Year	n/a
Reporting Currency	USD
CIK Code	0002058707
CUSIP Number	04987L102
ISIN Number	US04987L1026
SIC Code	2836